Cabometyx (cabozantinib) has no preset time limit. The FDA-approved prescribing information directs patients to continue taking it until the cancer progresses or side effects become unacceptable. Some people stay on it for months, others for years. The decision to stop is based on how well the drug is working and how well your body tolerates it, not on a fixed calendar.
What the Prescribing Guidelines Say
For kidney cancer (renal cell carcinoma) treated with Cabometyx alone, the label reads: continue at 60 mg once daily “until the patient no longer experiences clinical benefit or experiences unacceptable toxicity.” For liver cancer (hepatocellular carcinoma), the wording is nearly identical: continue until disease progression or unacceptable toxicity. When Cabometyx is paired with nivolumab (Opdivo) for kidney cancer, the same open-ended instruction applies to Cabometyx, though nivolumab itself is capped at two years.
In practical terms, “clinical benefit” means the cancer is stable or shrinking, and “unacceptable toxicity” means side effects that persist or worsen despite dose adjustments and supportive care. Your oncologist will monitor imaging scans and lab work at regular intervals to assess both.
How Long People Actually Stay on It
Clinical trials and real-world data show wide variation. In the CELESTIAL trial for advanced liver cancer, the median treatment duration was 3.8 months. That relatively short figure reflects the advanced stage of disease in those patients, many of whom had already been through prior treatments.
A real-world study of kidney cancer patients tracked treatment durations ranging from 1 month to 61 months (just over 5 years), with a median of 15 months. At the end of that study, 23% of patients who had not progressed were still taking Cabometyx. So while the “typical” duration lands somewhere in the range of several months to just over a year, a meaningful fraction of patients remain on the drug much longer. The researchers reported no new safety concerns in patients treated for extended periods and no treatment-related deaths.
Side Effects Often Shape the Timeline
Side effects are the most common reason treatment gets adjusted or stopped. In clinical trials, 92% of patients experienced at least one adverse event. The most frequent issues that force changes are diarrhea, hand-foot syndrome (painful redness and peeling on the palms and soles), fatigue, and high blood pressure.
These side effects don’t necessarily mean stopping the drug. Dose reductions and temporary pauses are the first line of defense. In the pivotal kidney cancer trial, 60% of patients needed at least one dose reduction, and 70% had treatment temporarily held at some point. About 20% of patients ended up on the lowest available dose (20 mg) and continued treatment. Only 10% permanently discontinued because of side effects.
In the combination trial with nivolumab, roughly 28% of patients discontinued one or both drugs due to treatment-related side effects. That higher number partly reflects the added burden of two therapies working simultaneously.
How Dose Adjustments Keep You on Treatment Longer
Cabometyx comes in three dose levels: 60 mg, 40 mg, and 20 mg. If side effects become difficult, your oncologist will typically step you down by 20 mg rather than stopping outright. Importantly, research suggests that reducing the dose does not significantly reduce the drug’s effectiveness. One study found no meaningful difference in survival outcomes between patients maintained at 40 mg and those reduced to 20 mg.
The specific side effects that most often trigger dose reductions are diarrhea (16% of patients), hand-foot syndrome (11%), fatigue (10%), and high blood pressure (about 8%). For diarrhea specifically, some form of dose modification was needed in 26% of patients. These adjustments are routine and expected, not a sign that treatment is failing.
Situations That Require Stopping
Certain serious events require permanent discontinuation. These include severe internal bleeding, a perforation (hole) in the gastrointestinal tract, a heart attack, blood clots requiring medical intervention, severe high blood pressure that cannot be controlled with medications, and a rare neurological condition called reversible posterior leukoencephalopathy syndrome. These events are uncommon but serious enough to rule out restarting the drug.
Liver function also plays a role. Patients with mild or moderate liver impairment start at a reduced dose of 40 mg. Those with severe liver impairment are generally not candidates for Cabometyx at all. If liver enzymes rise significantly during treatment, the dose is reduced or paused until levels normalize.
If you need surgery, including dental surgery, your oncologist will have you stop Cabometyx at least three weeks beforehand. The drug can impair wound healing, so this pause is standard.
A Counterintuitive Finding About Side Effects
One real-world study found something unexpected: patients who developed certain side effects, particularly underactive thyroid and hand-foot syndrome, actually lived significantly longer than those who didn’t. Patients with multiple side effects also had better survival outcomes than those with one or none. The researchers believe these side effects may signal that the drug is actively engaging its targets in the body. This doesn’t mean you should welcome severe side effects, but it may offer some reassurance if you’re experiencing manageable ones and wondering whether to continue.